Tarveda Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference

WATERTOWN, Mass.--()--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference, occurring March 2-4, 2020 in Boston. Tarveda presentation details:

Date: Monday, March 2, 2020
Time: 12:00pm Eastern Time
Location: Boston Marriott Copley Place, Boston, MA

About Tarveda Therapeutics®, Inc.

Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda’s Pentarin miniature drug conjugates are designed to take the best properties of both small molecule drugs and antibody drug conjugates to form a miniature drug conjugate able to penetrate into solid tumors, selectively bind to the desired tumor targets and accumulate the anti-cancer payloads directly in tumor cells. The anti-cancer payload is retained in tumor and then released over time causing the anti-cancer payload to become active in the tumor.

Tarveda currently has two Pentarin miniature drug conjugates in clinical trials. Its first clinical program, PEN-866, is its initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform. HSP90 is a molecular chaperone that is highly activated in the harsh tumor environment across a wide range of solid tumor cancers, but which remains relatively dormant in normal tissue. Tarveda’s binding moieties of its HSP90 binding miniature drug conjugates have been shown to bind with much higher affinity to the activated form of HSP90, which is typically overexpressed in tumor cells. PEN-866 is currently completing its Phase 1 dose escalation portion of its “all comers” trial in various types of solid tumors and is anticipating conclusion of this Phase 1 dose escalation study in the first quarter of 2020. In addition to PEN-866, Tarveda is developing additional miniature drug conjugates on its HSP90 binding miniature drug conjugate platform to target other promising anti-cancer payloads such as kinase inhibitors and radioisotopes to solid tumors. Tarveda’s second clinical program, PEN-221, is a Pentarin miniature drug conjugate currently in clinical evaluation for the treatment of patients with solid tumors expressing somatostatin receptor 2, or SSTR2, on the cell surface such as neuroendocrine tumors and small cell lung cancer. PEN-221 is currently progressing through its Phase 2a trial. For more information regarding Tarveda, go to: https://www.tarvedatx.com/.

Contacts

Amanda Houlihan
MacDougall
781 235 3060
ahoulihan@macbiocom.com

Release Summary

Tarveda Therapeutics announces that Drew Fromkin, President and CEO, will present at the Cowen & Company 40th Annual Health Care Conference.

Contacts

Amanda Houlihan
MacDougall
781 235 3060
ahoulihan@macbiocom.com